Catalina Nicora Santamarina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Catalina Nicora Santamarina has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Claudio Daniel Gonzalez
Department of Pharmacology, Biostatistics and Quantitative Medicine Section, Instituto Universitario CEMIC, Ciudad Autónoma de Buenos Aires 1430, Argentina
1 shared publication - Maria Ines Vaccaro
Universidad de Buenos Aires, Buenos Aires, Argentina
1 shared publication - María Paula Carro Negueruela
Instituto Universitario del Centro de Educacion Medica e Investigacion Clinica (IUC-CEMIC-CONICET), Facultad de Medicina, Instituto Universitario CEMIC, Buenos Aires C1430 EFA, Argentina
1 shared publication - Roxana Resnik
Instituto de Bioquimica y Medicina Molecular, Consejo Nacional de Investigaciones Cientificas y Tecnicas, Universidad de Buenos Aires, Buenos Aires C1425FQB, Argentina
1 shared publication
Latest Publications
- Open Access
Autophagy Dysregulation in Diabetic Kidney Disease: From Pathophysiology to Pharmacological Interventions
Diabetic kidney disease (DKD) is a frequent, potentially devastating complication of diabetes mellitus. Several factors are involved in its pathophysiology. At a cellular level, diabetic kidney disease is associated with many structural and functional alterations. Autophagy is a cellular mechanism that transports intracytoplasmic components to lysosomes to preserve cellular function and homeostasis. Autophagy integrity is essential for cell homeostasis, its alteration can drive to cell damage or death. Diabetic kidney disease is associated with profound autophagy dysregulation. Autophagy rate and flux alterations were described in several models of diabetic kidney disease. Some of them are closely linked with disease progression and severity. Some antidiabetic agents have shown significant effects on autophagy. A few of them have also demonstrated to modify disease progression and improved outcomes in affected patients. Other drugs also target autophagy and are being explored for clinical use in patients with diabetic kidney disease. The modulation of autophagy could be relevant for the pharmacological treatment and prevention of this disease in the future. Therefore, this is an evolving area that requires further experimental and clinical research. Here we discuss the relationship between autophagy and Diabetic kidney disease and the potential value of autophagy modulation as a target for pharmacological intervention.
Open AccessAutophagy Dysregulation in Diabetic Kidney Disease: From Pathophysiology to Pharmacological Interventions
Diabetic kidney disease (DKD) is a frequent, potentially devastating complication of diabetes mellitus. Several factors are involved in its pathophysiology. At a cellular level, diabetic kidney disease is associated with many structural and functional alterations. Autophagy is a cellular mechanism that transports intracytoplasmic components to lysosomes to preserve cellular function and homeostasis. Autophagy integrity is essential for cell homeostasis, its alteration can drive to cell damage or death. Diabetic kidney disease is associated with profound autophagy dysregulation. Autophagy rate and flux alterations were described in several models of diabetic kidney disease. Some of them are closely linked with disease progression and severity. Some antidiabetic agents have shown significant effects on autophagy. A few of them have also demonstrated to modify disease progression and improved outcomes in affected patients. Other drugs also target autophagy and are being explored for clinical use in patients with diabetic kidney disease. The modulation of autophagy could be relevant for the pharmacological treatment and prevention of this disease in the future. Therefore, this is an evolving area that requires further experimental and clinical research. Here we discuss the relationship between autophagy and Diabetic kidney disease and the potential value of autophagy modulation as a target for pharmacological intervention.